 | • レポートコード：MRC2Q12-18941 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥710,500 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,421,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、慢性閉塞性肺疾患臨床治療のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 慢性閉塞性肺疾患臨床治療のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 慢性閉塞性肺疾患臨床治療の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 慢性閉塞性肺疾患臨床治療のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの慢性閉塞性肺疾患臨床治療の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の慢性閉塞性肺疾患臨床治療の売上および2028年までの予測に焦点を当てています。 慢性閉塞性肺疾患臨床治療のグローバル主要企業には、Abbott、Akorn、AbbVie、AstraZeneca、Boehringer Ingelheim、Cipla、GSK、Merck、Mylan、Novartis、Pfizer、Roche、Teva、Vecturaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 慢性閉塞性肺疾患臨床治療市場は、タイプとアプリケーションによって区分されます。世界の慢性閉塞性肺疾患臨床治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 抗炎症薬、気管支拡張薬、その他 【アプリケーション別セグメント】 総合病院、専門クリニック 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 慢性閉塞性肺疾患臨床治療製品概要 - タイプ別市場（抗炎症薬、気管支拡張薬、その他） - アプリケーション別市場（総合病院、専門クリニック） - 調査の目的 ・エグゼクティブサマリー - 世界の慢性閉塞性肺疾患臨床治療販売量予測2017-2028 - 世界の慢性閉塞性肺疾患臨床治療売上予測2017-2028 - 慢性閉塞性肺疾患臨床治療の地域別販売量 - 慢性閉塞性肺疾患臨床治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別慢性閉塞性肺疾患臨床治療販売量 - 主要メーカー別慢性閉塞性肺疾患臨床治療売上 - 主要メーカー別慢性閉塞性肺疾患臨床治療価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（抗炎症薬、気管支拡張薬、その他） - 慢性閉塞性肺疾患臨床治療のタイプ別販売量 - 慢性閉塞性肺疾患臨床治療のタイプ別売上 - 慢性閉塞性肺疾患臨床治療のタイプ別価格 ・アプリケーション別市場規模（総合病院、専門クリニック） - 慢性閉塞性肺疾患臨床治療のアプリケーション別販売量 - 慢性閉塞性肺疾患臨床治療のアプリケーション別売上 - 慢性閉塞性肺疾患臨床治療のアプリケーション別価格 ・北米市場 - 北米の慢性閉塞性肺疾患臨床治療市場規模（タイプ別、アプリケーション別） - 主要国別の慢性閉塞性肺疾患臨床治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの慢性閉塞性肺疾患臨床治療市場規模（タイプ別、アプリケーション別） - 主要国別の慢性閉塞性肺疾患臨床治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の慢性閉塞性肺疾患臨床治療市場規模（タイプ別、アプリケーション別） - 主要国別の慢性閉塞性肺疾患臨床治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の慢性閉塞性肺疾患臨床治療市場規模（タイプ別、アプリケーション別） - 主要国別の慢性閉塞性肺疾患臨床治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの慢性閉塞性肺疾患臨床治療市場規模（タイプ別、アプリケーション別） - 主要国別の慢性閉塞性肺疾患臨床治療市場規模（トルコ、サウジアラビア） ・企業情報 Abbott、Akorn、AbbVie、AstraZeneca、Boehringer Ingelheim、Cipla、GSK、Merck、Mylan、Novartis、Pfizer、Roche、Teva、Vectura ・産業チェーン及び販売チャネル分析 - 慢性閉塞性肺疾患臨床治療の産業チェーン分析 - 慢性閉塞性肺疾患臨床治療の原材料 - 慢性閉塞性肺疾患臨床治療の生産プロセス - 慢性閉塞性肺疾患臨床治療の販売及びマーケティング - 慢性閉塞性肺疾患臨床治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 慢性閉塞性肺疾患臨床治療の産業動向 - 慢性閉塞性肺疾患臨床治療のマーケットドライバー - 慢性閉塞性肺疾患臨床治療の課題 - 慢性閉塞性肺疾患臨床治療の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Chronic Obstructive Pulmonary Disease Clinical Therapeutics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Chronic Obstructive Pulmonary Disease Clinical Therapeutics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Chronic Obstructive Pulmonary Disease Clinical Therapeutics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Chronic Obstructive Pulmonary Disease Clinical Therapeutics include Abbott, Akorn, AbbVie, AstraZeneca, Boehringer Ingelheim, Cipla, GSK, Merck and Mylan, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chronic Obstructive Pulmonary Disease Clinical Therapeutics manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Chronic Obstructive Pulmonary Disease Clinical Therapeutics market. Further, it explains the major drivers and regional dynamics of the global Chronic Obstructive Pulmonary Disease Clinical Therapeutics market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Abbott
Akorn
AbbVie
AstraZeneca
Boehringer Ingelheim
Cipla
GSK
Merck
Mylan
Novartis
Pfizer
Roche
Teva
Vectura
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Chronic Obstructive Pulmonary Disease Clinical Therapeutics Segment by Type
Anti-inflammatory Drugs
Bronchodilators
Others
Chronic Obstructive Pulmonary Disease Clinical Therapeutics Segment by Application
General Hospitals
Specialty Clinics
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Chronic Obstructive Pulmonary Disease Clinical Therapeutics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Chronic Obstructive Pulmonary Disease Clinical Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Chronic Obstructive Pulmonary Disease Clinical Therapeutics, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Chronic Obstructive Pulmonary Disease Clinical Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chronic Obstructive Pulmonary Disease Clinical Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Chronic Obstructive Pulmonary Disease Clinical Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Chronic Obstructive Pulmonary Disease Clinical Therapeutics sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Abbott, Akorn, AbbVie, AstraZeneca, Boehringer Ingelheim, Cipla, GSK, Merck and Mylan, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Chronic Obstructive Pulmonary Disease Clinical Therapeutics in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Disease Clinical Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chronic Obstructive Pulmonary Disease Clinical Therapeutics sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Introduction
1.2 Market by Type
1.2.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Anti-inflammatory Drugs
1.2.3 Bronchodilators
1.2.4 Others
1.3 Market by Application
1.3.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 General Hospitals
1.3.3 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales Estimates and Forecasts 2017-2028
2.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue Estimates and Forecasts 2017-2028
2.3 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Region
2.4.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Region (2017-2022)
2.4.2 Global Sales Chronic Obstructive Pulmonary Disease Clinical Therapeutics by Region (2023-2028)
2.5 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Region
2.5.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Region (2017-2022)
2.5.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Manufacturers
3.1.1 Global Top Chronic Obstructive Pulmonary Disease Clinical Therapeutics Manufacturers by Sales (2017-2022)
3.1.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Chronic Obstructive Pulmonary Disease Clinical Therapeutics in 2021
3.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Manufacturers
3.2.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Manufacturers (2017-2022)
3.2.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue in 2021
3.3 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Type
4.1.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Historical Sales by Type (2017-2022)
4.1.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Forecasted Sales by Type (2023-2028)
4.1.3 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales Market Share by Type (2017-2028)
4.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Type
4.2.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Historical Revenue by Type (2017-2022)
4.2.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Forecasted Revenue by Type (2023-2028)
4.2.3 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue Market Share by Type (2017-2028)
4.3 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Price by Type
4.3.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Price by Type (2017-2022)
4.3.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Application
5.1.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Historical Sales by Application (2017-2022)
5.1.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Forecasted Sales by Application (2023-2028)
5.1.3 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales Market Share by Application (2017-2028)
5.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Application
5.2.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Historical Revenue by Application (2017-2022)
5.2.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Forecasted Revenue by Application (2023-2028)
5.2.3 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue Market Share by Application (2017-2028)
5.3 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Price by Application
5.3.1 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Price by Application (2017-2022)
5.3.2 Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Price Forecast by Application (2023-2028)
6 North America
6.1 North America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Type
6.1.1 North America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Type (2017-2028)
6.1.2 North America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Type (2017-2028)
6.2 North America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Application
6.2.1 North America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Application (2017-2028)
6.2.2 North America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Application (2017-2028)
6.3 North America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Country
6.3.1 North America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Country (2017-2028)
6.3.2 North America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Type
7.1.1 Europe Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Type (2017-2028)
7.1.2 Europe Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Type (2017-2028)
7.2 Europe Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Application
7.2.1 Europe Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Application (2017-2028)
7.2.2 Europe Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Application (2017-2028)
7.3 Europe Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Country
7.3.1 Europe Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Country (2017-2028)
7.3.2 Europe Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Type
8.1.1 Asia Pacific Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Type (2017-2028)
8.1.2 Asia Pacific Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Type (2017-2028)
8.2 Asia Pacific Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Application
8.2.1 Asia Pacific Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Application (2017-2028)
8.2.2 Asia Pacific Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Application (2017-2028)
8.3 Asia Pacific Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Region
8.3.1 Asia Pacific Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Region (2017-2028)
8.3.2 Asia Pacific Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Type
9.1.1 Latin America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Type (2017-2028)
9.1.2 Latin America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Type (2017-2028)
9.2 Latin America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Application
9.2.1 Latin America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Application (2017-2028)
9.2.2 Latin America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Application (2017-2028)
9.3 Latin America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Country
9.3.1 Latin America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Country (2017-2028)
9.3.2 Latin America Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Type
10.1.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Type (2017-2028)
10.1.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Type (2017-2028)
10.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Application
10.2.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Application (2017-2028)
10.2.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Application (2017-2028)
10.3 Middle East and Africa Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Size by Country
10.3.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales by Country (2017-2028)
10.3.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Clinical Therapeutics Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Abbott
11.1.1 Abbott Corporation Information
11.1.2 Abbott Overview
11.1.3 Abbott Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Abbott Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Abbott Recent Developments
11.2 Akorn
11.2.1 Akorn Corporation Information
11.2.2 Akorn Overview
11.2.3 Akorn Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Akorn Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Akorn Recent Developments
11.3 AbbVie
11.3.1 AbbVie Corporation Information
11.3.2 AbbVie Overview
11.3.3 AbbVie Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 AbbVie Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 AbbVie Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Corporation Information
11.4.2 AstraZeneca Overview
11.4.3 AstraZeneca Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 AstraZeneca Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 AstraZeneca Recent Developments
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Corporation Information
11.5.2 Boehringer Ingelheim Overview
11.5.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Boehringer Ingelheim Recent Developments
11.6 Cipla
11.6.1 Cipla Corporation Information
11.6.2 Cipla Overview
11.6.3 Cipla Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Cipla Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Cipla Recent Developments
11.7 GSK
11.7.1 GSK Corporation Information
11.7.2 GSK Overview
11.7.3 GSK Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 GSK Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 GSK Recent Developments
11.8 Merck
11.8.1 Merck Corporation Information
11.8.2 Merck Overview
11.8.3 Merck Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Merck Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Merck Recent Developments
11.9 Mylan
11.9.1 Mylan Corporation Information
11.9.2 Mylan Overview
11.9.3 Mylan Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Mylan Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Mylan Recent Developments
11.10 Novartis
11.10.1 Novartis Corporation Information
11.10.2 Novartis Overview
11.10.3 Novartis Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Novartis Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Novartis Recent Developments
11.11 Pfizer
11.11.1 Pfizer Corporation Information
11.11.2 Pfizer Overview
11.11.3 Pfizer Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Pfizer Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Pfizer Recent Developments
11.12 Roche
11.12.1 Roche Corporation Information
11.12.2 Roche Overview
11.12.3 Roche Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Roche Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Roche Recent Developments
11.13 Teva
11.13.1 Teva Corporation Information
11.13.2 Teva Overview
11.13.3 Teva Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Teva Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Teva Recent Developments
11.14 Vectura
11.14.1 Vectura Corporation Information
11.14.2 Vectura Overview
11.14.3 Vectura Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Vectura Chronic Obstructive Pulmonary Disease Clinical Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Vectura Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Industry Chain Analysis
12.2 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Production Mode & Process
12.4 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales and Marketing
12.4.1 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Sales Channels
12.4.2 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Distributors
12.5 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Industry Trends
13.2 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Drivers
13.3 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Challenges
13.4 Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Restraints
14 Key Findings in The Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
| 【慢性閉塞性肺疾患臨床治療について】 慢性閉塞性肺疾患（COPD）は、慢性的な気道の炎症により気流制限を引き起こし、呼吸機能に影響を与える進行性の肺疾患です。この疾患は、慢性気管支炎および肺気腫の2種類に大別されることが多く、喫煙や大気汚染、職業性曝露などが主要なリスク因子として知られています。COPDは世界中での主要な健康問題の一つであり、特に高齢者において呼吸器疾患による死亡率を増加させる要因となっています。 COPDの特徴には、慢性的な呼吸器症状が含まれます。これには咳、痰の生成、息切れなどがあり、これらの症状は通常、運動時や日常生活の際に顕著になります。病状が進行するにつれて、安静時にも息切れを感じることが増え、日常生活が著しく制限されることがあります。これに加え、COPD患者はしばしば他の合併症、たとえば心血管疾患や骨粗しょう症、うつ病なども伴うことが多いです。 COPDの診断は、主に肺機能検査によって行われます。スパイロメトリーと呼ばれる呼吸機能検査を用いて、気流の閉塞の程度を評価します。この検査では、呼吸器による空気の流れを測定し、FEV1（1秒間に吐き出せる空気の量）とFVC（努力性肺活量）を基にした比率（FEV1/FVC）が用いられます。COPDでは、この比率が通常70％未満であることが特徴です。また、画像診断として胸部X線やCTスキャンが用いられ、肺の構造的変化を確認することもあります。 COPDの治療は、主に症状の管理と疾患の進行の抑制を目的としています。まず、喫煙者に対しては禁煙が最も重要な介入の一つです。禁煙によって症状の改善や病気の進行を遅らせることが示されています。次に、気管支拡張薬が広く用いられています。これにはβ2アドレナリン作動薬や抗コリン薬があり、気道の筋肉を弛緩させ、呼吸を楽にする効果があります。これらの薬剤は短時間作用型と長時間作用型があり、使用目的に応じて選択されます。 さらに、吸入ステロイドは特に慢性気管支炎型COPD患者において症状の緩和と急性増悪の防止に寄与します。併用療法として、気管支拡張薬と吸入ステロイドを組み合わせた治療も一般的に行われており、これにより患者の状態が大きく改善されることがあります。 リハビリテーションも重要な治療の一環です。特に呼吸リハビリテーションプログラムでは、運動療法や呼吸法、栄養指導などが行われ、患者の生活の質を向上させる助けとなります。さらに、酸素療法は、酸素飽和度が低い患者に対して行われることがあり、これにより日常生活の活動性が改善されることが期待されます。 近年では、新しい治療法や技術の研究が進められています。生物学的製剤や遺伝子治療の可能性についての研究が進行中であり、これによりCOPDの根本的な治療法の確立が期待されています。また、テクノロジーの進化に伴い、遠隔医療やモバイルアプリを活用した健康管理が普及してきています。これにより、患者は自らの健康状態をモニタリングし、医療機関との連携を強化することが可能となります。 さらに、公衆衛生の観点からも、COPDの予防と早期発見が重要視されています。早期の診断と介入が行われることで、症状の悪化を防ぎ、患者の生活の質を向上させることができます。そのためには、喫煙防止プログラムや大気汚染対策など、社会全体で取り組むべき課題が多々あります。 COPDは慢性病であるため、患者には長期的な管理と継続的な医療が必要です。患者自身も疾病管理に積極的に参加し、医師とのコミュニケーションを密にすることが求められます。家族や支援者の理解と協力も重要であり、患者の心理的・社会的な支えが症状改善に寄与することが多いです。 総じて、慢性閉塞性肺疾患は多面的なアプローチが求められる疾患であり、医療界と社会全体での協力が、患者の健康を守り、より良い生活を提供する鍵となります。治療法の進展や予防策の強化により、COPDの影響を受ける人々の生活の質を向上させることが期待されます。今後も研究と治療の発展が続く中で、COPDの管理がさらに進化することが望まれます。 |